SCHEMBL16387346

SCHEMBL16387346

C#C[C@]1(O)C(=C)CC2[C@@H]3CC=C4C=C(C)CCC4C3CC[C@@]21C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 6/20 0.41
▸ AR P10275 6/20 0.41
▸ ESR2 Q92731 4/20 0.41
▸ SRD5A2 P31213 2/20 0.40
▸ CYP3A4 P08684 4/20 0.37
▸ LMNA P02545 4/20 0.37
▸ PGR P06401 4/20 0.37
▸ ABCB11 O95342 3/20 0.37
▸ CYP2C19 P33261 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ HIF1A Q16665 2/20 0.37
▸ SHBG P04278 2/20 0.37
▸ NR3C1 P04150 2/20 0.37
▸ SLC6A4 P31645 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ PDK1 Q15118 2/20 0.36
▸ PDK2 Q15119 2/20 0.36
▸ PDK3 Q15120 2/20 0.36
▸ PDK4 Q16654 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16387361 1.00 ESR1 (0.41) ESR1ARESR2SRD5A2CYP3A4
SCHEMBL16387348 0.86 SRD5A2 (0.40) ESR1ARESR2SRD5A2
SCHEMBL16387359 0.86 SRD5A2 (0.40) ESR1ARESR2SRD5A2
SCHEMBL17634364 0.86 PGR (0.41) ESR1ARESR2SRD5A2CYP3A4
SCHEMBL16387350 0.86 PGR (0.41) ESR1ARESR2SRD5A2CYP3A4
SCHEMBL15079255 0.84 SRD5A2 (0.37) ESR1ARESR2SRD5A2CYP3A4
SCHEMBL17591517 0.84 SRD5A2 (0.37) ESR1ARESR2SRD5A2CYP3A4
SCHEMBL16389288 0.84 SRD5A2 (0.37) ESR1ARESR2SRD5A2CYP3A4
SCHEMBL15079265 0.84 SRD5A2 (0.37) ESR1ARESR2SRD5A2CYP3A4
SCHEMBL16387362 0.84 SRD5A2 (0.38) ESR1ARESR2SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296780-B2 Process for alkynylating 16-substituted-17-keto steroids CRYSTAL PHARMA, S.A.U. (ES) 2016-03-29 — — US disclosed
US-20150005518-A1 PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS CRYSTAL PHARMA, S.A.U. (ES) 2015-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005518-A1 PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS HSD17B7, NR3C2, CYP17A1 ESR1 258/4885AR 47/4885ESR2 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback